Tiziana Life Sciences is trading 5.8% up at $1.09 following positive Phase 2 PET imaging results from a Multiple System Atrophy (MSA) patient treated with intranasal foralumab.
- The imaging data showed significant reductions in brain inflammation markers, marking the third patient to demonstrate such improvements in the trial.
- Today's move extends sharp gains from the previous week as investor sentiment remains buoyed by the clinical update originally announced on July 31.